These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 22792454)

  • 1. The Role of p38 MAPK and Its Substrates in Neuronal Plasticity and Neurodegenerative Disease.
    Corrêa SA; Eales KL
    J Signal Transduct; 2012; 2012():649079. PubMed ID: 22792454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The p38
    Beamer E; Corrêa SAL
    Front Cell Dev Biol; 2021; 9():635636. PubMed ID: 33585492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease.
    Munoz L; Ammit AJ
    Neuropharmacology; 2010 Mar; 58(3):561-8. PubMed ID: 19951717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology.
    Maphis N; Jiang S; Xu G; Kokiko-Cochran ON; Roy SM; Van Eldik LJ; Watterson DM; Lamb BT; Bhaskar K
    Alzheimers Res Ther; 2016 Dec; 8(1):54. PubMed ID: 27974048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of p38 MAPK in Synaptic Function and Dysfunction.
    Falcicchia C; Tozzi F; Arancio O; Watterson DM; Origlia N
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developmental regulation of mitogen-activated protein kinase-activated kinases-2 and -3 (MAPKAPK-2/-3) in vivo during corpus luteum formation in the rat.
    Maizels ET; Mukherjee A; Sithanandam G; Peters CA; Cottom J; Mayo KE; Hunzicker-Dunn M
    Mol Endocrinol; 2001 May; 15(5):716-33. PubMed ID: 11328854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer's Disease.
    Lee JK; Kim NJ
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28767069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases.
    Yasuda S; Sugiura H; Tanaka H; Takigami S; Yamagata K
    Cent Nerv Syst Agents Med Chem; 2011 Mar; 11(1):45-59. PubMed ID: 20812905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revisiting p38 Mitogen-Activated Protein Kinases (MAPK) in Inflammatory Arthritis: A Narrative of the Emergence of MAPK-Activated Protein Kinase Inhibitors (MK2i).
    Ganguly P; Macleod T; Wong C; Harland M; McGonagle D
    Pharmaceuticals (Basel); 2023 Sep; 16(9):. PubMed ID: 37765094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation.
    Sheng JG; Jones RA; Zhou XQ; McGinness JM; Van Eldik LJ; Mrak RE; Griffin WS
    Neurochem Int; 2001; 39(5-6):341-8. PubMed ID: 11578769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitogen-activated protein kinase-activated protein kinase 2 in neuroinflammation, heat shock protein 27 phosphorylation, and cell cycle: role and targeting.
    Gurgis FM; Ziaziaris W; Munoz L
    Mol Pharmacol; 2014 Feb; 85(2):345-56. PubMed ID: 24296859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitogen-activated protein kinase p38 and MK2, MK3 and MK5: ménage à trois or ménage à quatre?
    Shiryaev A; Moens U
    Cell Signal; 2010 Aug; 22(8):1185-92. PubMed ID: 20227494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p38 MAPK and PI3K/AKT Signalling Cascades inParkinson's Disease.
    Jha SK; Jha NK; Kar R; Ambasta RK; Kumar P
    Int J Mol Cell Med; 2015; 4(2):67-86. PubMed ID: 26261796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of c-Jun N-terminal kinase (JNK)/p38 mitogen-activated protein kinase (p38 MAPK) in morphine-induced tau protein hyperphosphorylation.
    Cao M; Liu F; Ji F; Liang J; Liu L; Wu Q; Wang T
    Behav Brain Res; 2013 Jan; 237():249-55. PubMed ID: 23026374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sec6 enhances cell migration and suppresses apoptosis by elevating the phosphorylation of p38 MAPK, MK2, and HSP27.
    Tanaka T; Iino M; Goto K
    Cell Signal; 2018 Sep; 49():1-16. PubMed ID: 29729335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marathon running increases ERK1/2 and p38 MAP kinase signalling to downstream targets in human skeletal muscle.
    Yu M; Blomstrand E; Chibalin AV; Krook A; Zierath JR
    J Physiol; 2001 Oct; 536(Pt 1):273-82. PubMed ID: 11579175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine regulation by MAPK activated kinase 2 in keratinocytes exposed to sulfur mustard.
    Yego EC; Dillman JF
    Toxicol In Vitro; 2013 Oct; 27(7):2067-75. PubMed ID: 23851002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of p38/MAPKs in Alzheimer's disease: implications for amyloid beta toxicity targeted therapy.
    Kheiri G; Dolatshahi M; Rahmani F; Rezaei N
    Rev Neurosci; 2018 Dec; 30(1):9-30. PubMed ID: 29804103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-1β-induced and p38
    Kulawik A; Engesser R; Ehlting C; Raue A; Albrecht U; Hahn B; Lehmann WD; Gaestel M; Klingmüller U; Häussinger D; Timmer J; Bode JG
    J Biol Chem; 2017 Apr; 292(15):6291-6302. PubMed ID: 28223354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct cellular functions of MK2.
    Kotlyarov A; Yannoni Y; Fritz S; Laass K; Telliez JB; Pitman D; Lin LL; Gaestel M
    Mol Cell Biol; 2002 Jul; 22(13):4827-35. PubMed ID: 12052889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.